Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Onconetix, Inc. (Nasdaq: ONCO) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering a structured view of how this commercial-stage biotechnology company reports on its men’s health and oncology business. Onconetix’s filings span registration statements, current reports, and proxy materials, each providing different angles on its operations, capital structure, and governance.
Through registration statements on Form S‑1 and S‑1/A, Onconetix details equity financing arrangements such as PIPE transactions involving Series D and Series E convertible preferred stock and associated warrants, as well as an equity line of credit with Keystone Capital Partners. These documents describe the number of shares registered for resale, conversion and exercise prices, and the company’s status as a smaller reporting company and emerging growth company. They also explain the impact of the company’s 1‑for‑85 reverse stock split on share counts and per‑share data.
Current reports on Form 8‑K provide timely disclosure of material events, including PIPE financing closings, licensing agreements, promissory notes, Nasdaq listing notices, and strategic transactions. For example, 8‑K filings describe the terms of the Series D and Series E preferred stock and warrants, the licensing agreement between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and amendments and waivers associated with promissory notes tied to the ENTADFI asset acquisition.
The company’s definitive proxy statement on Schedule 14A outlines proposals for stockholder approval, such as director elections, ratification of the independent registered public accounting firm, and approvals required under Nasdaq rules for issuing common stock upon conversion of preferred stock and exercise of warrants. These materials also confirm the date and location of the annual meeting and summarize the board’s recommendations.
On Stock Titan, each new 10‑K, 10‑Q, 8‑K, S‑1, DEF 14A, or other filing is captured as it becomes available from EDGAR. AI-powered tools can be used to highlight key sections, such as risk factors, descriptions of Proclarix and ENTADFI, financing terms, and Nasdaq compliance disclosures. Users interested in insider activity can also review Form 4 filings, when available, to see reported transactions by directors and officers.
By using this page, investors and researchers can quickly locate Onconetix’s quarterly and annual reports, capital raising disclosures, and governance documents, and rely on AI summaries to interpret complex sections without reading every page of the underlying filings.
Onconetix, Inc. announced multiple board changes. Effective April 20, 2026, directors Andrew Oakley and Thomas Meier resigned from the board and their committee roles. Their departures were stated as not resulting from any disagreement with management or the board on company matters.
On April 23, 2026, existing director Sammy Dorf was appointed Chairman of the Board and will receive an additional $20,000 per year, paid quarterly, for this role. The board also elected Josh Epstein as a Class II director and member of the Audit Committee and Compensation Committee, and chair of the Nominating and Corporate Governance Committee, with a term running until the 2026 annual meeting of stockholders.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported an open-market sale of 49,710 Class A Shares at $0.69 per share. After this transaction, HRT Financial LP directly holds 33,649 Class A Shares of Onconetix.
This Form 4 reflects a net reduction in HRT Financial LP’s position, with no derivative securities reported as remaining holdings in this filing.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported several open-market trades in Class A Shares. On April 16, 2026 and April 20, 2026 it sold a total of 148,329 shares at about $0.73–$0.75 per share, and on April 17, 2026 it purchased 34,636 shares at $0.73. Overall, this was a net sale of 113,693 shares, leaving HRT Financial LP with 83,359 Class A Shares held directly after the last reported transaction.
Onconetix, Inc. major holder HRT FINANCIAL LP increased its stake with open-market purchases of Class A Shares. The investor bought 92,554 shares at $0.76 per share on April 15, 2026 and 74,350 shares at $0.77 per share on April 14, 2026. After these transactions, HRT FINANCIAL LP directly holds 197,052 Class A Shares, reflecting net buying activity over the two days.
Onconetix, Inc. disclosed that HRT FINANCIAL LP is a ten percent owner and filed an initial ownership report. The filing shows HRT FINANCIAL LP directly holds 104,498 Class A Shares of Onconetix common equity. This is a status report of existing holdings, not a new purchase or sale.
Onconetix provides an update on its pending acquisition of Realbotix LLC, stating it entered into a definitive share exchange to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
Onconetix highlights Realbotix’s April 8, 2026 delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci is described as a patented AI vision and eye-tracking system that enables Realbotix robots to recognize returning users, recall prior conversations, maintain eye contact, and track engagement; Vinci can be added to any Realbotix robot model.
Onconetix, Inc. summarizes Realbotix's update that Realbotix expects delivery of 19 previously ordered humanoid robots and associated AI implementations across March, April, and May 2026. Onconetix previously entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all‑stock transaction. The combined company is expected to trade on Nasdaq following closing, which Onconetix anticipates in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. Onconetix states it will file a Registration Statement on Form S-4 to register shares to be issued in the transaction.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026 and Sammy Dorf as a director and Audit Committee member effective March 19, 2026.
The company states these leadership changes come as it advances a definitive agreement to acquire Realbotix LLC and intends to file a Registration Statement on Form S-4 to register Onconetix common stock to be issued in the transaction.
Onconetix, Inc. is asking stockholders at an April 30, 2026 special meeting to approve authority for one or more reverse stock splits of its common stock at ratios between 1-for-2 and 1-for-10, with all such splits together capped at 1-for-100 and usable for one year.
The aim is to maintain compliance with Nasdaq’s $1.00 minimum bid requirement after prior notices under the Bid Price Rule and Low Priced Stocks Rule, and to support liquidity and future capital-raising. A second proposal would allow adjournment of the meeting to solicit additional proxies. There were 692,927 common shares outstanding as of March 13, 2026.
Onconetix, Inc. filed an initial insider ownership report for Chief Executive Officer David Allan White on Form 3. This filing establishes his status as an executive officer and subject to insider reporting rules, but it does not disclose any specific stock transactions or option exercises.